Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
Noradrenergic Add-on Therapy With Guanfacine
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 148
- Registration Number
- NCT03116126
- Locations
- 🇬🇧
Imperial Memory Unit, Charing Cross Hospital, London, United Kingdom
Guanfacine for PONV and Pain After Sinus Surgery
- Conditions
- Pain, PostoperativePostoperative Nausea and Vomiting
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 84
- Registration Number
- NCT02882854
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic
- Conditions
- Obstructive Sleep Apnea
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 41
- Registration Number
- NCT02699125
CRT-Guanfacine for SPD
- Conditions
- Schizotypal Personality DisorderSPD
- Interventions
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 45
- Registration Number
- NCT02524899
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 38
- Registration Number
- NCT02259517
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)
- Conditions
- Chronic Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02192398
- Locations
- 🇺🇸
MGH Center for Translational Pain Research, Boston, Massachusetts, United States
Does Guanfacine Attenuate Stress-Induced Drinking?
- Conditions
- Alcohol Drinking
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Yale University
- Target Recruit Count
- 70
- Registration Number
- NCT02164422
- Locations
- 🇺🇸
Yale Center for Clinical Investigations, Yale University, New Haven, Connecticut, United States
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).
- Conditions
- Adult Attention-Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Rochester Center for Behavioral Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT02141113
- Locations
- 🇺🇸
Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
ADHD Medication and Predictors of Treatment Outcome
- Conditions
- Attention Deficit Disorder With Hyperactivity (ADHD)
- Interventions
- Drug: lisdexamphetamine medication
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 632
- Registration Number
- NCT02136147
- Locations
- 🇸🇪
Division for Child and Adolescent Psychiatry in Stockholm, Stockholm, Stockholm County, Sweden
Guanfacine Clinical Trial for Smoking Cessation
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Yale University
- Target Recruit Count
- 121
- Registration Number
- NCT02051309
- Locations
- 🇺🇸
Yale Center for Clinical Investigations, Yale University, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.